Evommune, Inc. (NYSE:EVMN – Free Report) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Evommune in a research report issued on Monday, December 1st. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($2.52) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Evommune’s FY2026 earnings at ($2.57) EPS.
Several other brokerages have also recently weighed in on EVMN. Morgan Stanley assumed coverage on shares of Evommune in a report on Monday. They issued an “overweight” rating and a $36.00 target price on the stock. William Blair began coverage on shares of Evommune in a research report on Monday. They issued an “outperform” rating on the stock. Zacks Research raised shares of Evommune to a “hold” rating in a research report on Tuesday. Wall Street Zen upgraded shares of Evommune to a “hold” rating in a research note on Thursday, November 20th. Finally, Leerink Partners initiated coverage on Evommune in a report on Monday. They issued an “outperform” rating and a $42.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $39.33.
Evommune Stock Performance
Shares of EVMN opened at $21.97 on Wednesday. Evommune has a 1 year low of $16.70 and a 1 year high of $24.03.
Evommune Company Profile
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.
Recommended Stories
- Five stocks we like better than Evommune
- What Are Treasury Bonds?
- The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
- Canadian Penny Stocks: Can They Make You Rich?
- Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
- Comparing and Trading High PE Ratio Stocks
- Strong Quarter, Weak Reaction: Why GitLab Shares Dropped
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
